FindTrial
Sign In

Observational Study on the Efficacy of Brentuximab Vedotin-Based Therapies for Cutaneous T-Cell Lymphoma (CTCL) and an Exploration of Factors Affecting Treatment Outcomes

Observational Study on the Efficacy of Brentuximab Vedotin-Based Therapies for Cutaneous T-Cell Lymphoma (CTCL) and an Exploration of Factors Affecting Treatment Outcomes

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600128760
Enrollment
Unknown
Registered
2026-07-24
Start date
2026-07-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary cutaneous T-cell Lymphoma

Interventions

BV-Based therapy group:None

Sponsors

Huashan Hospital affiliated to Fudan university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years, male or female; 2.Chinese citizenship; 3.Patients with CTCL who have received brentuximab vedotin-based therapy in the Department of Hematology, Huashan Hospital, Fudan University.

Exclusion criteria

Exclusion criteria: 1.Patients with severely missing key clinical data, including but not limited to final pathological diagnosis, essential treatment information, efficacy and safety assessments, or follow-up data.

Design outcomes

Primary

MeasureTime frame
PFS;objective response rate;—

Secondary

MeasureTime frame
Clinical characteristics;Response rate;Onset time;Duration of progress;Disease control rate;Duration of disease control;Duration of disease remission;Quality of life and safety;—

Countries

China

Contacts

Public ContactWang Qian

Huashan Hospital affiliated to Fudan university

wangqian2004_2@126.com+86 21 52887102

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 10, 2026